Sodium Chloride 0.9% w/v. Nasal drops, 20 ml
2 drops in each nostril up to 4 times/d.
For the relief of nasal congestion in children and infants
C/I: hypersens.
peroxisome proliferator-activated receptor delta (PPARδ) agonist. Seladelpar 10 mg. Caps: 30 X 10 mg
Recomm. dose: 10 mg once daily.
For prim. biliary cholangitis (PBC) in combin. with ursodeoxycholic acid (UDCA) in adlts who have an inadequate resp. to UDCA alone, or as monother. in those unable to toler. UDCA.
C/I: Hypersens.
Antivirals. Bulevirtide 2 mg/ml. Vial. Pwder. for sol. for inj. 30 X 2 mg
Manage the underlying hepatitis B virus (HBV) infect. simultan. according to the official guidelines. To be admin. 1/d by SC inject. Recomm. dosage is 2 mg 1/d as long as clin. benef. is seen.
Tmt.of chronic hepatitis delta virus (HDV) infect. in plasma (or serum) HDV-RNA posit. adults with compensated liver dis.
C/I: Hypersens.
Drug class Cross-linked polyacrylic acid sodium salt, hydroxy propyl
methyl cellulose (HPMC), titanium dioxide, cellulose acetate
phthalate, hydroxypropyl cellulose, chitosan, diethyl
phthalate, polyvinyl alcohol polyethylene copolymer
(Kollicoat), triethyl citrate, cellulose acetate, acetyl tributyl
citrate.
Caps. X 56
1 cap. before meal X 2/d
Reducing BW in pts with 25 < BMI < 40 in conjunction with diet and exercise.
C/I: Hypersens. Pregn
Corticosteroid. Budesonide 2 mg. Canister with 14 X of 1.2 g
One actuation of 2 mg /d
Tmt of act. ulcerative colitis limited to the rectum and the sigmoid colon
C/I: Hypersens. /hepatic cyrrhosis
Anti-CD20, Human Monoclonal Antibody. Ocrelizumab 40 mg/ml. Vial. 1 X 920 mg for SC inject.
single 23 mL in the abdomen over approx. 10 minutes every 6 months.
For adults with relapsing or primary progress. forms of multiple sclerosis.
C/I:Hypersens. Active HBV infection/ A hist. of life-threatening admin. reaction to ocrelizumab
סונגורין מעכב מיטופגיה באי-ספיקת לב כרונית דרך מסלול TBC1D15/Fis1/Rab7A
ההשפעות האנטי-פיברוטיות של טיפולים תרופתיים חדשים לאי-ספיקת לב בחולים עם אי-ספיקת לב מתקדמת
סמן ביולוגי אמין ומדויק לאבחנה מבדלת בטרשת נפוצה
טיפול באובאיטיס קדמית לא זיהומית: דאזדוטופטיד לעומת סטרואידים
השפעת מצב סוציואקונומי על איכות הטיפול בסרטן גינקולוגי של האגן
שינויים בטווח התנועה של הכתף לאחר ניתוח בקרב חולות סרטן שד
כלי הדמיה אמין לרדיותרפיה בסרטן הרקטום: דימות מונו-אנרגטי וירטואלי
יעילות חיסון אימהי ב-Tdap5 למניעת שעלת בתינוקות
לעלון לצרכן לחצו כאן
הודעה על עדכון בעלון של התכשירים:
Cresemba 100 mg Capsules - לפרטים נוספים לחץ כאן
Cresemba 200 mg IV - לפרטים נוספים לחץ כאן
Ixifi - לפרטים נוספים לחץ כאן
Xanax X.R - לפרטים נוספים לחץ כאן
Diflucan 50mg/ml-לפרטים נוספים לחצו כאן
Trican 200 mg-לפרטים נוספים לחצו כאן
Triflucan I.V-לפרטים נוספים לחצו כאן
IXIFI-לפרטים נוספים לחצו כאן
Corticosteroid, Vitamin D Analogue. Betamethasone (as dipropionate) 0.5 mg/g, Calcipotriol (as monohydrate) 50 mcg/g. ALUMINIUM CAN:60 g.
Enstilar foam should be applied to the affected area once dly. The recom. tmt. period is 4 wks. The dly. max. dose should not exceed 15 g, i.e. one 60 g can should last for at least 4 d. 15 g corresponds to the amount admin. from the can if the actuator is fully depressed for approx. one minute. A two-second application delivers approx. 0.5 g. As a guide, 0.5 g of foam should cover an area of skin roughly correspond. to the surface area of an adult hand. Concomit. use with other topic. products contain. calcipotriol in addition to Enstilar: the total dose of all calcipotriol contain. products should not exceed 15 g/d. The total bdy. surf. area treated should not exceed 30%.
Ren. / hep. impair. The safety and efficacy in pts. with severe renal insuffic. or severe Hep. disord. have not been evaluated.
Ped. population:The safety and efficacy in child. below 18 yrs. have not been establish. Enstilar is not indic. for child<18 yrs. of age.
Topical tmt. of psoriasis vulgaris in adults.
C/I: Hypersens.
Pts. with erythrodermic and pustular psorias.
Pts. with known calcium metabolism disord.
Monobenzone Like Depigmentation Agent. Hydroquinone 4%. GEL: 60 g. Start with 1 applic. a day for
10-15 d. on skin spots and contin. with
2 x dly morn. and even.
Lighten. skin spots.
C/I: Child. under 12 yrs., tmt. of
hyperpigmentat. resulted from chemic.
ochronosis & degeneration colloid
(colloid milium) both from employment
as cosmet.
Histamine H1 Antagonist 2nd Generation. Bilastine 20 mg. TABS.: 20 mg. Adult. and adolesc. (12 yrs. of age and over) 1 tab×1/d for the relief of sympt. of allergic rhino-conjunctivit. (SAR and PAR) and urticaria. The tab. should be taken 1/2h. before after intake of food or fruit juice.
Indic. the symptom. tmt. of allerg. rhino-conjunctiv. (season. and perenn.) and urticaria in adult. and adolesc.(12 yrs. of age and over).
C/I: Hypersens.
SNRI. Duloxetine 30 , 60 mg. CAPS.:30. For diabet. peripher. neuropath. pain: The usual dose is 60 mg ×1/d.
For chron. musculoskel. pain and general. anxiety disord.: For most pts.
60 mg ×1/d. Some pts. require an init. dose of Dulox Teva 30 mg ×1/d for one wk., and then the usual dose of
60 mg ×1/d.
For depression: Most pts. will receive 60 mg ×1/d. Some pts. require an init. dose of Dulox Teva 30 mg ×1/d for one wk., and then the usual dose of 60 mg ×1/d
Elderly – The init. dose of 30 mg ×1/d for two wks., and only then consider incr. the dose to 60 mg ×1/d.
Fibromyalgia: The init. dose of Dulox Teva is 30 mg ×1/d for one wk., and then the usual dose of 60 mg ×1/d. In most cases, the effect of medication ther. with Dulox Teva is noticeab. after 2-4 wks. of tmt.
See lit.
Tmt. of major depressive episodes.
Managem. of neuropath.pain associat. with diabet. peripher. neuropathy.
Tmt. of generaliz. anxiety disord. (GAD).
Manag. of fibromyalgia.
Manag. of chron. muscoskel. pain when other therapies have failed or are
contraindic. This has been establish. in studies in pts. with chron. low back pain (CLBP) and chron. pain due to osteoarthritis.
C/I: Hypersens.
Pts. with hep. dis.
Pts. with severe ren. dis..
Concom. use with MAOI includ. IV methylene blue and the antibiot.linezolid. MAOI should be discount. 14 d. before init.of the tmt. with duloxetine.
Initiat. of MAOI should be start. at least 5 d. after discount. of the tmt. with duloxetine.
Concom. use with thioridazine
CCB, Local Anesthetic. Lidocaine HCl 1.5%, Nifedipine 0.3%. RECTAL CR.: 30g. Should be applied twice dly. for at least 3 wks. See lit.
Tmt. of anal fissures and proctolog. general. associate. with anal sphincter hypertonia.
C/I: Hypersens. to the active ingred., partic. to Lidocaine (& other local anesthet. with a similar amidic type structure). Presumed or ascertained preg. & lact.
Corticosteroid. Fluticasone Propionate 0.05%. METERED NASAL SPRAY: 120 doses. 2
sprays into ea. nostril 1 x dly. Child:
4-12 yrs: 1 spray into ea. nostril 1 x dly.
Under 4 yrs: Not recommended.
Proph. and tmt. seasonal allerg. rhinit.
incl. hayfever, perennial rhinit.
C/I: Hypersens. Concomitt. use with HIV drugs.
Antihistamine, Decongestant. Loratadine 5 mg, Pseudoephedrine Sulphate 120 mg. TABS: 14. One tab. ×2/d with a glass of water. The durat. of tmt. should be kept as short as possible. It is advisable to limit tmt. to about 10 d.
Relief of sympt. of season. allerg. rhinitis when both the antihistam. properties and the nasal decongest. activity are desired.
C/I: Hypersens. Pts. who are receiv. irrevers. MAO inhib. ther. or during the 2 wks. follow. the stop. of such tmt., and in pts. with: narrow-ang. glauc., urin.retent., cardiovasc. dis. (e.g. ischaem. heart dis., tachyarrhythm. sev. hypertens. hyperthyroid)., Pts. with hist. of haemorhag. stroke or with risk fact. which could incr. the risk of haemorhag. stroke (in comb. with other vasoconstrict. such as bromocripitine, pergolide, lisuride, cabergoline, ergotamine, dihydroergotamine or any other decongest. meds. used as a nasal decongest., either by oral route or by nasal route, e.g. phenylpropanolamine, phenylephrine, ephedrine, oxymetazoline, naphazoline).
Nicotine Receptor Partial Agonist. Varenicline (as tartrate) 0.5 mg, 1 mg. Health basket inclusion: Champix will be given to the treatment of smoking cessation parallel to supportive means.
TABS: 55 x 0.5 mg, 56 x 1 mg; starter pack: 11 x 0.5 mg + 14, 28 x 1 mg.
Days 1 – 3: 0.5 mg ×1/d.
Days 4– 7: 0.5 mg ×2/d.
Day 8 – end of tmt.: 1 mg ×2/d.
Pts. should be treated with Varenicline for 12 wks. For pts. who have successf. stopped smok. at the end of 12 wks., an addit. course of 12 wks. tmt. with Varenicline is recomm. to further incr. the likelihood of long-term abstinence.
Pts. with ren. impair. No dosage adjust. is necessary for pts. with mild- moder. renal impair. For pts. with sev. renal impair. (estimated CrCl <30 mL/min), the recomm. start. dose of Varenicline is 0.5 mg ×1/d. The dose may then be titrated as needed to a max. dose of 0.5 mg×2/d. For pts. with end-stage renal dis. underg. hemodialysis, a max. dose of 0.5 mg mg×/d may be admin. if toler.
Aid to smoking cessat. for adults over 18
yrs.
C/I: Hypersens., known skin react. to varenicline
Decongestant. Pseudoephedrine HCl 60 mg. TABS: 10, 20 x 60 mg. Adults and
children above 12 years 1 tab. every 6
hrs. Not more than 4 tabs dly.
Nasal and sinus congest.
